<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01329887</url>
  </required_header>
  <id_info>
    <org_study_id>TPO 736</org_study_id>
    <nct_id>NCT01329887</nct_id>
  </id_info>
  <brief_title>The Effect of Ketanserin on the Microcirculation in Sepsis</brief_title>
  <official_title>Evaluation of the Effect of Ketanserine on Sublingual Microcirculation by SDF Imaging in Septic Patients on the Intensive Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Centre Leeuwarden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Centre Leeuwarden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an evaluation of the effect of ketanserine on sublingual microcirculation in
      intensive care patients with severe sepsis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study, including 10 ICU patients with severe sepsis with MFI &lt; 2,5 after
      fulfillment of a strict resuscitation protocol. At the start of the study, a baseline SDF
      measurement is made, when MFI &lt; 2,5 inclusion in the study is permitted and intravenous
      ketanserin administration is started and subsequently increased, guided by the effect on
      sublingual MFI, until a safe maximum dosage is reached. Safety margins for hypotension are
      defined in the study protocol.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>microcirculation</measure>
    <time_frame>2 hours</time_frame>
    <description>achievement of a microvascular flow index &gt;2,9</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ketanserine dosage</measure>
    <time_frame>48 hours</time_frame>
    <description>obtaining a global indication of the ketanserin dosage needed to achieve a MFI &gt;2,9 and the incidence of hypotension</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Severe Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>administration of ketanserin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketanserin</intervention_name>
    <description>ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr</description>
    <arm_group_label>administration of ketanserin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe sepsis and MFI &lt; 2,5 after resuscitation

        Exclusion Criteria:

          -  age &lt; 18 year old

          -  pregnant

          -  participation other trials prolonged Qt interval
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E Boerma, MDPhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Centre Leeuwarden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical Centre Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2011</study_first_submitted>
  <study_first_submitted_qc>April 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2011</study_first_posted>
  <last_update_submitted>May 8, 2014</last_update_submitted>
  <last_update_submitted_qc>May 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Centre Leeuwarden</investigator_affiliation>
    <investigator_full_name>E.C. Boerma</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>microcirculation</keyword>
  <keyword>SDF</keyword>
  <keyword>ketanserin</keyword>
  <keyword>severe sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketanserin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

